Recruiting
Phase 2

MH002

Sponsor:

MRM Health NV

Code:

NCT07296315

Conditions

Colitis, Ulcerative

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

Low-dose MH002

High-dose MH002

Placebo

Study Details

Brief summary:

The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated.

MH002 is a live biotherapeutic product (LBP). This is a biological medicine containing live bacteria used to restore the normal function of a gut that is damaged by ulcerative colitis (UC). Ulcerative colitis is a bowel disease that causes inflammation and sores in the gut.

Conditions

Colitis, Ulcerative

Study ID

NCT07296315

Start date

Apr 3, 2026

Status verified date

Jun, 2026

Completion date

May, 2028

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Documented diagnosis (histologic diagnosis and either endoscopic or radiographic diagnosis) of ulcerative colitis (UC) at least 3 months prior to Screening.
  • Diagnosis of active mild-to-moderate UC at Screening as defined by an mMS of 4 to 7, including a MES ≥2 (confirmed by central reading), a Mayo Rectal Bleeding score of 1 or 2, and a Mayo Stool Frequency score ≥1.
  • UC lesions extending ≥10 cm from the anal verge.
  • Participant must either receive a stable dose of orally administered 5-aminosalicylic acid (5-ASA); have failed, due to insufficient efficacy, oral 5-ASA; have a documented intolerance or poor tolerance to an aminosalicylic acid treatment, including 5-ASA, or be contra-indicated to receive 5-ASA treatment per local labeling.
  • Participant must provide written informed consent or assent (parent or legal guardian must provide consent for a participant <18 years of age who has assented to participate in the study, or as required per local regulations).
  • In countries not allowing females of childbearing potential (FOCBP) to participate without an acceptable contraceptive method, the FOCBP must agree to abide to local requirements and eg, use at least an acceptable method of contraception until the end of treatment.

Exclusion Criteria:

  • Diagnosis of Crohn's disease, undetermined colitis, ischemic colitis, fulminant colitis, or toxic megacolon.
  • Evidence of a clinically significant, active infection of the gastrointestinal tract.
  • Severe UC (mMS>7), meeting modified Truelove Witts' criteria and/or RB score of 3, participant with ulcerative proctitis only, or participant in whom colitis is most severe in the transverse colon or ascending colon, or if any hospitalization is planned at the time of Screening.
  • Total colectomy, stoma, or ileo-anal pouch, or history of extensive colonic resection leaving less than 30 cm of colon.
  • Presence of intra-abdominal fistula, abscesses, diverticulitis, or gastrointestinal bleeding unrelated to UC.
  • History of colon carcinoma or high-grade dysplasia.
  • Previous use of any advanced UC treatment, including any anti-TNF (eg, infliximab), antiintegrin (eg, vedolizumab) or anti-IL-12/23 (eg, ustekinumab) agent, anti-IL23 (eg, risankizumab), Janus kinase inhibitors (eg, tofacitinib), and sphingosine-1-phosphate receptor modulators (eg, etrasimod).
  • Use of sulfasalazine ≤4 weeks prior to randomization.
  • Use of corticosteroids or any disease-modifying antirheumatic drugs (DMARD), including thiopurines, ≤6 weeks prior to randomization into the study, except for a stable, low dose of oral corticosteroids (≤10 mg prednisolone/day) for at least 2 weeks prior to Screening colonoscopy and up to at least the Week 12 visit.
  • Use of antibiotics (except for local use), prebiotics, or probiotics ≤4 weeks prior to randomization or anticipated during study participation, or concomitant, chronic use of an antidiarrheal drug, or concomitant use of any rectal treatment.
  • Use of fecal microbiota transplantation (FMT) ≤52 weeks prior to randomization.
  • Treatment with another investigational drug or intervention within 30 days prior to Screening, or within 5 times the elimination half-life of the investigational drug (whichever is longest).
  • Any immunocompromised state, including conditions linked to severe immunosuppression (eg, active human immunodeficiency virus, malignancies, liver cirrhosis, systemic chemotherapy).
  • Leukopenia (total white blood cell count <3000/μL) and/or neutropenia (absolute neutrophil count <1000/μL), anemia (hemoglobin <10.0 g/dL), thrombocytopenia (peripheral blood platelet count <100 × 10\^9/L), and/or any coagulation disorder with significantly increased risk of bleeding.
  • Ongoing or recent (<3 months) renal disease or insufficiency as manifested, eg, by medical history and/or clinical examination and/or (calculated or measured) glomerular filtration rate ≤60 mL/min.
  • Ongoing or recent (<3 months) advanced hepatic dysfunction defined as a Child Pugh score ≥10 (Class C), or increase ≥2 times the upper limit of normal in aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT) or international normalised ratio (INR).
  • Clinically significant bone marrow disease if progressive or not controlled, or any history of solid organ or bone marrow transplantation.
  • Active intravenous drug abuse or alcohol abuse disorder as assessed by the Investigator.
  • Pregnancy or lactation at study entry. Note: Participants who become pregnant or start to breastfeed during the study may continue the study per the Investigator's discretion.
  • Participants who are inappropriate for the study per the Investigator's discretion.
  • An employee (or a relative of) of the Investigator, study center, contract research organization, or Sponsor.

Study Design

Enrollment

204 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Low-dose MH002

experimental: High-dose MH002

placebo comparator: Placebo

Interventions

Low-dose MH002

Microbiome-based live biotherapeutic product consisting of 6 wildtype commensal strains at a dose of 1 × 10\^10 equivalent colony forming units \[eqCFU\]), administered orally (in a capsule) once daily

High-dose MH002

Microbiome-based live biotherapeutic product consisting of 6 wildtype commensal strains at a dose of 4 × 10\^10 equivalent colony forming units \[eqCFU\]), administered orally (in a capsule) once daily

Placebo

Blank placebo administered orally (in a capsule) once daily

Primary outcome measure

  • Change from baseline in centrally-assessed Mayo Endoscopic Subscore (MES) at Week 12. [ Time Frame: Week 12 ]

Central Contacts and Locations

Central contacts

Jean-Michel Muhlinghaus, DVM

+32 9 277 08 50clinicaltrials@mrmhealth.com

Carmen Fleurinck, MD

+32 9 277 08 50

Locations

ARA Professionals

Recruiting

Miami, Florida, United States, 33155

Orlando Gastroenterology, P.A.

Recruiting

Orlando, Florida, United States, 32835

Tropical Clinical Trials

Recruiting

Palmetto Bay, Florida, United States, 33176

Cross Creek Medical Clinic

Recruiting

Fayetteville, North Carolina, United States, 28304

Peters Medical Research

Recruiting

High Point, North Carolina, United States, 27260

Southern Star Research Institute

Recruiting

San Antonio, Texas, United States, 78229

More Information

Sponsor

MRM Health NV

Last update posted

Jul 9, 2026

Last verified

Jun, 2026

Keywords

  • 5-aminosalicylic-acid
  • live biotherapeutic product
  • ulcerative colitis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by MRM Health NV on 2026-07-09.